Quick Answer
Q32 Bio Inc. reported R&D Expense of $19.16 million for fiscal year 2025.
Q32 Bio Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.16M | -60.2% |
| 2024 | $48.14M | +51.7% |
| 2023 | $31.73M | -67.7% |
| 2022 | $98.35M | +5.7% |
| 2021 | $93.08M | -7.3% |
| 2020 | $100.39M | +12.3% |
| 2019 | $89.40M | +86.4% |
| 2018 | $47.95M | +124.3% |
| 2017 | $21.38M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.56M | -75.2% | -31.1% |
| June 30, 2025 | $5.16M | -61.5% | -27.6% |
| March 31, 2025 | $7.12M | -27.6% | -50.3% |
| September 30, 2024 | $14.35M | +92.2% | +7.0% |
| June 30, 2024 | $13.41M | +67.3% | +36.3% |
| March 31, 2024 | $9.84M | +24.4% | +31.9% |
| September 30, 2023 | $7.46M | -71.1% | -6.9% |
| June 30, 2023 | $8.02M | -62.0% | +1.4% |
- Q32 Bio Inc. showed a decrease of -60.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Q32 Bio Inc.’s r&d expense has declined by 10.4% (from $21.38 million to $19.16 million).
- The most recent figure is from Q32 Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: